Vnitřní lékařství 2/2020

P Ř EHLEDOVÉ Č LÁNKY Stárnutí cév a vaskulární pam ěť 110 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(2): 104–110 / www.casopisvnitrnilekarstvi.cz 9. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: A randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389–396. doi:10.1177/2047487313518479. 10. PapakatsikaS,StabouliS,AntzaC,KotsisV.EarlyVascularAging:ANewTarget forHyperten- sionTreatment.CurrPharmDes.2015;22(1):122–126.doi:10.2174/1381612822666151109112813. 11. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressu- re lowering by short-term and long-term antihypertensive treatment: A meta-analysis of individual data in 294 patients. J Hypertens. 2011; 29(6): 1034–1042. doi: 10.1097/ HJH.0b013e328346a583. 12. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006; 48(1): 80–86. doi: 10.1161/01.HYP.0000224283.76347.8c. 13. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arte- rial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013; 26(5): 608–616. doi:10.1093/ajh/hps098. 14. Meng X, Qie L, Wang Y, Zhong M, Li L. Assessment of arterial stiffness affected by ator- vastatin in coronary artery disease using pulse wave velocity. Clin Investig Med. 2009; 32(6): 238–243. 15. Ballard KD, Taylor BA, Capizzi JA, Grimaldi AS, White CM, Thompson PD. Atorvastatin Treatment Does Not Alter Pulse Wave Velocity in Healthy Adults. Int Sch Res Not. 2014; 2014: 1–5. doi: 10.1155/2014/239575. 16. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomogra- phy: the EASY-FIT study. J Am Coll Cardiol. 2014; 64(21): 2207–2217. 17. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardio- vascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643–2653. doi: 10.1056/NEJMoa052187. 18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensi- ve glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589. doi: 10.1056/ NEJMoa0806470. 19. Simes J, Simes RJ, Hunt D, et al. Long-term effectiveness and safety of pravasta- tin in 9014 patients with coronary heart disease and average cholesterol concen- trations: The LIPID trial follow-up. Lancet. 2002; 359(9315): 1379–1387. doi: 10.1016/ S0140-6736(02)08351-4. 20. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 2011; 32(20): 2525–2532. doi: 10.1093/eurheartj/ehr333. 21. Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long-term effects of Ra- mipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Cir- culation. 2005; 112(9): 1339–1346. doi: 10.1161/CIRCULATIONAHA.105.548461. 22. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure- -lowering and lipid-lowering treatment in patients with hypertension in the Anglo- -Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137. doi: 10.1016/S0140- 6736(18)31776-8. 23. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lan- cet Commission on hypertension. Lancet 2016; 388: 2665–2712. Vydáváme knihy oceňované odbornými lékařskými společnostmi Aktuální NOVINKA: Prohlédněte si ukázky publikací dostupných v našem e-shopu na www.solen.cz Cena děkana LF UP za významnou publikační činnost za rok 2013 v kategorii monografie a 2. místo v literární soutěži České internistické společnosti. Cena České onkologické společnosti za nejlepší knižní publikaci 2017 a také 1. místo v soutěži České urologické společnosti o nejlepší vědeckou publikaci za rok 2017 v kategorii „Monografie nebo postgraduální učební text“.